Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-04T01:56:45.145Z Has data issue: false hasContentIssue false

First report of mirtazapine-induced arthralgia

Published online by Cambridge University Press:  16 April 2020

P. Jolliet*
Affiliation:
Laboratory of Pharmacology, University of Nantes, 1 rue Gaston Veil, 44035, Nantes cedex1, France
G. Veyrac
Affiliation:
Laboratory of Pharmacology, University of Nantes, 1 rue Gaston Veil, 44035, Nantes cedex1, France
M. Bourin
Affiliation:
Laboratory of Pharmacology, University of Nantes, 1 rue Gaston Veil, 44035, Nantes cedex1, France
*
*Correspondence and reprints. E-mail address:pascale.jolliet@sante.univ-nantes.fr (P. Jolliet).
Get access

Summary

Objective.

The aim of our work is to describe the first two cases of arthralgia associated with the antidepressant drug mirtazapine.

Method.

Descriptive analysis of two iatrogenic cases. The review of the literature was achieved by the traditional electronic methods. The French database of iatrogenic cases was consulted.

Results.

A 53-year-old man presented with gonalgia after some weeks of mirtazapine treatment. The intensity of the arthralgia was correlated with the dosage and the adverse effect rapidly disappeared after the antidepressant therapy was stopped. A 38-year-old woman received mirtazapine for 3 months and complained of arthralgia and myalgia. This clinical picture was suspended as the drug was stopped and a positive reintroduction was observed. No other cause was found in these two patients.

Discussion.

No similar case has been reported in the international literature, but several observations of arthralgia with mianserin are mentioned. As mirtazapine is the 6-aza derivative of the tetracyclic antidepressant mianserin, the similarities of their chemical structures begs the responsibility of mirtazapine for arthralgia.

Type
Case Reports
Copyright
Copyright © 2001 Éditions scientifiques et médicales Elsevier SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bannwarth, B.Drug-induced rheumatic disorders. Rev Rhum Engl 1996; 63: 639–47.Google ScholarPubMed
Barkin, FJ.A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59: 123–7.Google Scholar
Fawcett, JBarkin, RL.Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267–85.CrossRefGoogle ScholarPubMed
Holm, KJMarkham, A.Mirtazapine: a review of its use in major depression. Drugs 1999; 57: 607–31.CrossRefGoogle ScholarPubMed
Hugues, ACoote, J.Arthropathy associated with treatment with mianserin. Br Med J 1986; 292: 1050.Google Scholar
Kasper, SPraschak-Rieder, NTauscher, J.A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17: 251–64.CrossRefGoogle ScholarPubMed
Meyboon, RHEdwards, IREgberts, AC.Mirtazapine and the granulocytes–so far so good. N Z Med J 1999; 112: 104.Google Scholar
Nelson, JC.Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997; 58: 2631.Google ScholarPubMed
Ostensen, M.Mianserin as a cause of arthritis. Br J Rheumatol 1991; 30: 74–5.CrossRefGoogle ScholarPubMed
Otani, K.Hepatic injury caused by mianserin. Br Med J 1989; 299: 519–21.CrossRefGoogle ScholarPubMed
Roose, SP.Tolerability and patient compliance. J Clin Psychiatry 60Suppl 171999 14–7.Google ScholarPubMed
Thompson, C.Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60 (Suppl 17): 1822.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.